The Department of Health, Abu Dhabi (DoH) has announced that AstraZeneca signed an agreement with artificial intelligence (AI)-powered healthcare company G42 Healthcare to locally produce drugs in Abu Dhabi, UAE.

The binding agreement is centred on collaborating in four key areas that include localising industries, research and development, innovation, and sustainability at a global scale.

According to the DoH, the deal is the newest in a series of partnerships with key firms in the pharmaceutical industry and will position the UAE as a hub for research and innovation in life sciences.

G42 Healthcare and the UK-based biopharmaceutical firm will use Abu Dhabi’s healthcare infrastructure to manufacture medications.

With a focus on delivering advanced medication and boosting exports, the agreement is expected to expand Abu Dhabi’s footprint in life science research and development as well as support innovation. It will also seek to advance sustainable solutions while striking a balance between economic growth and sustainability.

G42 Healthcare CEO Ashish Koshy said: “We are confident in the potential of our continuing partnership with AstraZeneca which holds a robust promise for the UAE healthcare sector, primed to become a global hub for life science research and innovation.

“This strategic collaboration will accelerate innovation across local manufacturing and allow us to explore greater possibilities in clinical research, to deliver life-changing treatments to patients in the UAE and across the region.

“At the core of this partnership is our will to foster sustainable manufacturing capabilities and driving innovation at the global level, as we collectively envision better healthcare for all.”

According to the DOH, the agreement between the two firms aligns with the Make it in the Emirates initiative and the National Strategy for Industry and Advanced Technology. Both programmes are intended to improve the business environment and draw domestic and international industrial investors to the UAE.